Li-Fraumeni syndrome: cancer risk assessment and clinical management KA McBride, ML Ballinger, E Killick, J Kirk, MHN Tattersall, RA Eeles, ... Nature reviews Clinical oncology 11 (5), 260-271, 2014 | 277 | 2014 |
Monogenic and polygenic determinants of sarcoma risk: an international genetic study ML Ballinger, DL Goode, I Ray-Coquard, PA James, G Mitchell, ... The Lancet Oncology 17 (9), 1261-1271, 2016 | 221 | 2016 |
Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis ML Ballinger, A Best, PL Mai, PP Khincha, JT Loud, JA Peters, MI Achatz, ... JAMA oncology 3 (12), 1634-1639, 2017 | 171 | 2017 |
Diagnosis of fusion genes using targeted RNA sequencing EE Heyer, IW Deveson, D Wooi, CI Selinger, RJ Lyons, VM Hayes, ... Nature communications 10 (1), 1-12, 2019 | 153 | 2019 |
TGF-β stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2 ML Burch, SNY Yang, ML Ballinger, R Getachew, N Osman, PJ Little Cellular and Molecular Life Sciences 67, 2077-2090, 2010 | 111 | 2010 |
Regulation of glycosaminoglycan structure and atherogenesis ML Ballinger, J Nigro, KV Frontanilla, AM Dart, PJ Little Cellular and Molecular Life Sciences CMLS 61, 1296-1306, 2004 | 106 | 2004 |
A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma L Mirabello, R Koster, BS Moriarity, LG Spector, PS Meltzer, J Gary, ... Cancer discovery 5 (9), 920-931, 2015 | 94 | 2015 |
Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis PJ Little, ML Ballinger, N Osman Vascular health and risk management 3 (1), 117, 2007 | 94 | 2007 |
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice B Leroy, ML Ballinger, F Baran-Marszak, GL Bond, A Braithwaite, ... Cancer research 77 (6), 1250-1260, 2017 | 86 | 2017 |
Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease KJ Grande-Allen, N Osman, ML Ballinger, H Dadlani, S Marasco, PJ Little Cardiovascular research 76 (1), 19-28, 2007 | 83 | 2007 |
Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor β type I … ML Burch, ML Ballinger, SNY Yang, R Getachew, C Itman, K Loveland, ... Journal of Biological Chemistry 285 (35), 26798-26805, 2010 | 81 | 2010 |
Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo ML Ballinger, N Osman, K Hashimura, JB Haan, K Jandeleit‐Dahm, ... Journal of cellular and molecular medicine 14 (6b), 1408-1418, 2010 | 77 | 2010 |
Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle H Dadlani, ML Ballinger, N Osman, R Getachew, PJ Little Journal of biological chemistry 283 (12), 7844-7852, 2008 | 71 | 2008 |
High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort G Mitchell, ML Ballinger, S Wong, C Hewitt, P James, MA Young, ... PloS one 8 (7), e69026, 2013 | 69 | 2013 |
PDGF β-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL R Getachew, ML Ballinger, ML Burch, JJ Reid, LM Khachigian, TN Wight, ... Endocrinology 151 (9), 4356-4367, 2010 | 63 | 2010 |
Biosynthesis of natural and hyperelongated chondroitin sulfate glycosaminoglycans: new insights into an elusive process PJ Little, ML Ballinger, ML Burch, N Osman The open biochemistry journal 2, 135, 2008 | 63 | 2008 |
Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counselling for hereditary cancer: a systematic review AM Willis, SK Smith, B Meiser, ML Ballinger, DM Thomas, MA Young Clinical genetics 92 (2), 121-133, 2017 | 58 | 2017 |
Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? KA McBride, ML Ballinger, TE Schlub, MA Young, MHN Tattersall, J Kirk, ... Familial cancer 16, 423-432, 2017 | 48 | 2017 |
Therapeutic implications of germline genetic findings in cancer S Thavaneswaran, E Rath, K Tucker, AM Joshua, D Hess, M Pinese, ... Nature Reviews Clinical Oncology 16 (6), 386-396, 2019 | 47 | 2019 |
Surveillance recommendations for patients with germline TP53 mutations ML Ballinger, G Mitchell, DM Thomas Current opinion in oncology 27 (4), 332-337, 2015 | 47 | 2015 |